mTOR in Metabolism and Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".
Deadline for manuscript submissions: closed (30 March 2024) | Viewed by 3080
Special Issue Editor
Interests: cancer; metabolism; mRNA translation; mRNA degradation; mTOR
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mechanistic target of rapamycin (mTOR) integrates extracellular and intracellular signals (e.g., growth factors, insulin, nutrients, and oxygen) to stimulate anabolism, including protein and lipid synthesis, and bolster cellular growth and proliferation while suppressing autophagy. mTOR forms two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which differ in their composition, downstream targets, regulation, and sensitivity to the naturally occurring allosteric mTOR inhibitor rapamycin. Dysregulation of the mTOR signaling pathway frequently accompanies diseases characterized by perturbations in energy metabolism and cell growth, such as cancer and metabolic syndrome. The first generation of mTOR inhibitors, rapamycin and its analogs, have been used for the treatment of several types of cancer with modest therapeutic effects. Chronic rapamycin significantly increases lifespan in model organisms with better health indicators. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic domain show potent and comprehensive inhibition and are currently being tested in clinics. The major clinical benefits of mTOR inhibition will likely be in the prevention or management of age-related diseases such as cancer and metabolic syndrome and its associated complications, resulting in late-life morbidity compression.
Continuing from the previous Issue, this Special Issue will cover a selection of recent research topics and current review articles in the field of the mTOR pathway and its impacts on metabolism and cancers.
Dr. Masahiro Morita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mTOR
- rapamycin
- inhibitor
- cancer
- metabolic syndrome
- aging
- mRNA translation
- 4E-BP
- S6K
- autophagy
